Stock Financial Ratios, Dividends, Split History

DLB / Dolby Laboratories, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)3,899.15
Enterprise Value ($M)5,928.03
Book Value ($M)2,147.43
Book Value / Share34.39
Price / Book1.90
NCAV ($M)702.00
NCAV / Share11.24
Price / NCAV5.82
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 101,784,000
Common Shares Outstanding2 42,873,597
Weighted Average Number Of Diluted Shares Outstanding 103,286,000
Common Shares Outstanding 59,415,802
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.09
Return on Assets (ROA)0.09
Return on Equity (ROE)0.10
Balance Sheet (mrq) ($M)
Quick Ratio5.30
Current Ratio5.42
Income Statement (mra) ($M)
Sales Revenue Services Net20,372,000.00
Licenses Revenue965,792,000.00
Concentration Of Revenue From Individual Geographic Regions1.00
Sales Revenue Goods Net95,290,000.00
Operating Income248.63
Net Income202.43
Earnings Per Share Diluted1.95
Earnings Per Share Basic1.98
Cash Flow Statement (mra) ($M)
Cash From Operations371.05
Cash from Investing-161.73
Cash from Financing-161.73
Identifiers and Descriptors
Central Index Key (CIK)1308547
Related CUSIPS
25659T907 025659T10 25659T957

Split History

Stock splits are used by Dolby Laboratories, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

21h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

Dolby (DLB) Eyes Expansion in Europe, Clinches Dual Deals

2018-06-14 zacks
In the 2018 CineEurope trade show, Dolby Laboratories, Inc. (DLB - Free Report) announced its plans to expand operations into the European cinema market. In addition to this, the company also advertised its non-imitable imaging, audio, post-production and accessibility technology in the expo. In sync with the aforementioned plan, Dolby Laboratories has inked an agreement with Odeon Cinemas Group — an acquired business arm of AMC Entertainment Holdings, Inc. (44-0)

Apple Adds More Fitness Features, Walkie-Talkie App to Its Watch - Bloomberg

2018-06-04 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (253-1)

In order to grow, we need to get into other markets: Vince Voron

2018-05-27 livemint
Mumbai: No matter where you are or what you do, there is a good chance that Vince Voron has had a hand in creating products that you use on a daily basis. The global vice-president of design and brand at Dolby Laboratories started his career as an industrial design manager at Apple, where he was involved in the development of the iMac, Powerbook, iPod and iPhone. (3-0)

Why Is Dolby Laboratories (DLB) Down 6.1% Since its Last Earnings Report?

2018-05-25 zacks
A month has gone by since the last earnings report for Dolby Laboratories (DLB - Free Report) . Shares have lost about 6.1% in that time frame. (9-0)

Dolby Laboratories (DLB) Q2 Earnings & Revenues Top Estimates

2018-04-25 zacks
Dolby Laboratories, Inc. (DLB - Free Report) reported second-quarter fiscal 2018 adjusted earnings of 78 cents per share, beating the Zacks Consensus Estimate of 77 cents. (12-0)

CUSIP: 25659T107